DOCG.L vs. BIOG.L

Last updated Apr 2, 2026

Compare and contrast key facts about L&G Healthcare Breakthrough UCITS ETF (DOCG.L) and The Biotech Growth Trust plc (BIOG.L).

DOCG.L is a passively managed fund by Legal & General that tracks the performance of the MSCI World/Health Care NR USD. It was launched on Jun 26, 2019.

Performance

DOCG.L vs. BIOG.L - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in L&G Healthcare Breakthrough UCITS ETF (DOCG.L) and The Biotech Growth Trust plc (BIOG.L). The values are adjusted to include any dividend payments, if applicable.

DOCG.L vs. BIOG.L - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
DOCG.L L&G Healthcare Breakthrough UCITS ETF	-5.52%	16.50%	3.57%	-6.64%	-25.94%	1.46%	63.33%	0.69%
BIOG.L The Biotech Growth Trust plc	6.67%	40.35%	-4.36%	-3.46%	-22.05%	-24.62%	67.66%	21.76%

Returns By Period

In the year-to-date period, DOCG.L achieves a -5.52% return, which is significantly lower than BIOG.L's 6.67% return.

DOCG.L

• 1D: 2.82%
• 1M: -4.55%
• YTD: -5.52%
• 6M: 9.15%
• 1Y: 20.30%
• 3Y*: 1.87%
• 5Y*: -4.46%
• 10Y*: —

BIOG.L

• 1D: 1.59%
• 1M: 1.19%
• YTD: 6.67%
• 6M: 24.88%
• 1Y: 71.12%
• 3Y*: 17.80%
• 5Y*: -2.60%
• 10Y*: 7.69%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DOCG.L vs. BIOG.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DOCG.L

DOCG.L Risk / Return Rank: 46
DOCG.L Sharpe Ratio Rank: 49
DOCG.L Sortino Ratio Rank: 51
DOCG.L Omega Ratio Rank: 41
DOCG.L Calmar Ratio Rank: 46
DOCG.L Martin Ratio Rank: 41

BIOG.L

BIOG.L Risk / Return Rank: 92
BIOG.L Sharpe Ratio Rank: 93
BIOG.L Sortino Ratio Rank: 90
BIOG.L Omega Ratio Rank: 88
BIOG.L Calmar Ratio Rank: 95
BIOG.L Martin Ratio Rank: 95

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DOCG.L vs. BIOG.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for L&G Healthcare Breakthrough UCITS ETF (DOCG.L) and The Biotech Growth Trust plc (BIOG.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DOCG.L	BIOG.L	Difference
Sharpe ratio Return per unit of total volatility	0.94	2.45	-1.50
Sortino ratio Return per unit of downside risk	1.43	2.92	-1.49
Omega ratio Gain probability vs. loss probability	1.17	1.38	-0.20
Calmar ratio Return relative to maximum drawdown	1.34	5.83	-4.49
Martin ratio Return relative to average drawdown	4.28	17.13	-12.84
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DOCG.L vs. BIOG.L - Sharpe Ratio Comparison

The current DOCG.L Sharpe Ratio is 0.94, which is lower than the BIOG.L Sharpe Ratio of 2.45. The chart below compares the historical Sharpe Ratios of DOCG.L and BIOG.L, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DOCG.L	BIOG.L	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.94	2.45	-1.50
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.20	-0.10	-0.10
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.28	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.19	0.35	-0.16

Correlation

The correlation between DOCG.L and BIOG.L is 0.60, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

DOCG.L vs. BIOG.L - Dividend Comparison

Neither DOCG.L nor BIOG.L has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

DOCG.L vs. BIOG.L - Drawdown Comparison

The maximum DOCG.L drawdown since its inception was -51.45%, smaller than the maximum BIOG.L drawdown of -85.07%. Use the drawdown chart below to compare losses from any high point for DOCG.L and BIOG.L.

Drawdown Indicators

	DOCG.L	BIOG.L	Difference
Max Drawdown Largest peak-to-trough decline	-51.45%	-85.07%	+33.62%
Max Drawdown (1Y) Largest decline over 1 year	-15.66%	-15.76%	+0.10%
Max Drawdown (5Y) Largest decline over 5 years	-49.65%	-57.68%	+8.03%
Max Drawdown (10Y) Largest decline over 10 years	—	-64.29%	—
Current Drawdown Current decline from peak	-31.80%	-26.27%	-5.53%
Average Drawdown Average peak-to-trough decline	-26.99%	-36.80%	+9.81%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.92%	4.32%	+0.60%

Volatility

DOCG.L vs. BIOG.L - Volatility Comparison

The current volatility for L&G Healthcare Breakthrough UCITS ETF (DOCG.L) is 6.90%, while The Biotech Growth Trust plc (BIOG.L) has a volatility of 9.89%. This indicates that DOCG.L experiences smaller price fluctuations and is considered to be less risky than BIOG.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DOCG.L	BIOG.L	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.90%	9.89%	-2.99%
Volatility (6M) Calculated over the trailing 6-month period	14.26%	21.07%	-6.81%
Volatility (1Y) Calculated over the trailing 1-year period	21.47%	28.94%	-7.47%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	21.95%	26.36%	-4.41%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	23.42%	27.39%	-3.97%